About CalciMedica, Inc.
https://www.calcimedica.comCalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.
CEO
A. Rachel Leheny
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-03-20 | Reverse | 1:14 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:1.3M
Value:$7.14M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:683.9K
Value:$3.75M
AISLING CAPITAL MANAGEMENT LP
Shares:521.11K
Value:$2.86M
Summary
Showing Top 3 of 33
About CalciMedica, Inc.
https://www.calcimedica.comCalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $5.62M ▼ | $-7.8M ▼ | 0% | $-0.52 ▼ | $-7.48M ▼ |
| Q2-2025 | $0 | $6.62M ▲ | $-5.96M ▼ | 0% | $-0.4 ▼ | $-5.62M ▼ |
| Q1-2025 | $0 | $6.5M ▲ | $-5.04M ▼ | 0% | $-0.36 ▼ | $-4.58M ▼ |
| Q4-2024 | $0 | $6.16M ▲ | $-4.26M ▲ | 0% | $-0.33 ▲ | $-4.24M ▲ |
| Q3-2024 | $0 | $5.74M | $-5.62M | 0% | $-0.5 | $-5.72M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $14.08M ▼ | $14.91M ▼ | $15.18M ▲ | $-268K ▼ |
| Q2-2025 | $17.96M ▼ | $19.08M ▼ | $12.98M ▼ | $6.1M ▼ |
| Q1-2025 | $24.63M ▲ | $25.35M ▲ | $14.46M ▲ | $10.89M ▼ |
| Q4-2024 | $18.67M ▲ | $19.79M ▲ | $5.38M ▼ | $14.41M ▲ |
| Q3-2024 | $14.6M | $16.21M | $7.18M | $9.03M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.8M ▼ | $-4.78M ▲ | $3.51M ▲ | $818K ▲ | $-448K ▲ | $-4.79M ▲ |
| Q2-2025 | $-5.96M ▼ | $-6.67M ▼ | $134K ▲ | $-102K ▼ | $-6.64M ▼ | $-6.67M ▼ |
| Q1-2025 | $-5.04M ▼ | $-4.88M ▲ | $-1.24M ▲ | $10.74M ▲ | $4.62M ▲ | $-4.89M ▲ |
| Q4-2024 | $-4.26M ▲ | $-4.97M ▼ | $-5.17M ▼ | $8.92M ▲ | $-1.22M ▼ | $-4.97M ▼ |
| Q3-2024 | $-5.62M | $-4.67M | $8.75M | $16K | $4.09M | $-4.67M |
CEO
A. Rachel Leheny
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-03-20 | Reverse | 1:14 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
Shares:1.3M
Value:$7.14M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:683.9K
Value:$3.75M
AISLING CAPITAL MANAGEMENT LP
Shares:521.11K
Value:$2.86M
Summary
Showing Top 3 of 33